Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Aiman Waheed, MBBS
Advertisement
Articles by Aiman Waheed, MBBS
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Advertisement
Latest Updated Articles
Efficacy and Safety of Zolbetuximab in Gastric CancerPublished: December 6th 2024 | Updated:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentPublished: August 14th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
